[go: up one dir, main page]

GB202319768D0 - Cell model of pathogenic short tandem repeat diseases and associated cell-based assay - Google Patents

Cell model of pathogenic short tandem repeat diseases and associated cell-based assay

Info

Publication number
GB202319768D0
GB202319768D0 GBGB2319768.4A GB202319768A GB202319768D0 GB 202319768 D0 GB202319768 D0 GB 202319768D0 GB 202319768 A GB202319768 A GB 202319768A GB 202319768 D0 GB202319768 D0 GB 202319768D0
Authority
GB
United Kingdom
Prior art keywords
cell
pathogenic
based assay
tandem repeat
short tandem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2319768.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loqus23 Therapeutics Ltd
Original Assignee
Loqus23 Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loqus23 Therapeutics Ltd filed Critical Loqus23 Therapeutics Ltd
Priority to GBGB2319768.4A priority Critical patent/GB202319768D0/en
Publication of GB202319768D0 publication Critical patent/GB202319768D0/en
Priority to PCT/GB2024/053149 priority patent/WO2025133602A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2319768.4A 2023-12-21 2023-12-21 Cell model of pathogenic short tandem repeat diseases and associated cell-based assay Pending GB202319768D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2319768.4A GB202319768D0 (en) 2023-12-21 2023-12-21 Cell model of pathogenic short tandem repeat diseases and associated cell-based assay
PCT/GB2024/053149 WO2025133602A1 (en) 2023-12-21 2024-12-18 Cell model of pathogenic short tandem repeat diseases and associated cell-based assay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2319768.4A GB202319768D0 (en) 2023-12-21 2023-12-21 Cell model of pathogenic short tandem repeat diseases and associated cell-based assay

Publications (1)

Publication Number Publication Date
GB202319768D0 true GB202319768D0 (en) 2024-02-07

Family

ID=89767996

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2319768.4A Pending GB202319768D0 (en) 2023-12-21 2023-12-21 Cell model of pathogenic short tandem repeat diseases and associated cell-based assay

Country Status (2)

Country Link
GB (1) GB202319768D0 (en)
WO (1) WO2025133602A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP3314241B2 (en) 1992-04-06 2002-08-12 ヤマハ発動機株式会社 Exhaust gas purification device for motorcycle engine
JP3151657B2 (en) 1997-03-26 2001-04-03 農林水産省農業生物資源研究所長 Gene transfer method
US10509045B2 (en) * 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease

Also Published As

Publication number Publication date
WO2025133602A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
HUP2400426A1 (en) Negative electrode suspension preparation and application
Ngouana et al. Investigation of minor species Candida africana, Candida stellatoidea and Candida dubliniensis in the Candida albicans complex among Yaoundé (Cameroon) HIV‐infected patients
GB202319768D0 (en) Cell model of pathogenic short tandem repeat diseases and associated cell-based assay
Sureau et al. Rabies diagnosis by animal inoculation, identification of Negri bodies, or ELISA
Nataraj et al. Safety evaluation of indigenous probiotic Limosilactobacillus fermentum NCDC 400 using whole genome sequences and in vitro approaches
Sánchez et al. Extracellular DNase activity of Cryptococcus neoformans and Cryptococcus gattii
Juntachai et al. Ambient pH regulates secretion of lipases in Malassezia furfur
BRPI0915156A2 (en) methods for optimizing cell culture viability and productivity
GB202410348D0 (en) Method for measuring gene expression of single cell subpopulation, related kit, and application
IL323652A (en) Conditionally immortalized stem cells and uses thereof
Rymovicz et al. Screening of reducing agents for anaerobic growth of Candida albicans SC5314
Chowdhury et al. Dynamic compression influences interleukin-1β-induced nitric oxide and prostaglandin E2 release by articular chondrocytes via alterations in iNOS and COX-2 expression
IL286558B1 (en) Method of culturing cell population and use thereof
IL318030A (en) Multi-chamber cell culture system and method
GB202306238D0 (en) Motile cell analysis
EP4361255A4 (en) CELL CULTURE PROCESS, CELL CULTURE KIT AND CELL CULTURE SYSTEM
Taylor Early motor development is part of the resource mix for language acquisition–a commentary on Iverson's ‘Developing language in a developing body: the relationship between motor development and language development’
EP3969568A4 (en) IN VITRO CELL CULTURE SYSTEM FOR THE PRODUCTION OF HEPATOCYTE-LIKE CELLS AND THEIR USES
AU2023901013A0 (en) Cell cultures and methods of use thereof
ZA202206921B (en) Kit for rapid assay of probiotic activity and assay method thereof
Sullivan et al. Development of a Human in Vitro Model of Lung Epithelial Senescence Highlights the Cell-Type Specific Response to Telomere Dysfunction
RU2553513C2 (en) Method of obtaining bifidogenic factor
HUE071895T2 (en) Methods of handling biological cell cultures
Mislej The city of Trieste as the center of the attention to the person: an historical and cultural framework of the enabling nursing, a fertile ground for the development of Engagement: Trieste culla dell’attenzione alla persona: un inquadramento storico e culturale del nursing abilitante e di iniziativa, terreno fertile per lo sviluppo dell’Engagement
GB202300548D0 (en) Suspension cell culture